Abstract: An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided.

Abstract: The present invention relates to an antibody in which a motif composed of an amino acid or peptide sequence including one or more cysteine residues is bound to the terminus of a parent antibody, particularly the terminus of the heavy chain of the parent antibody. Also, the present invention relates to a modified antibody-drug conjugate (mADC) comprising a drug bound to the antibody, and a method for producing the antibody or the modified antibody-drug conjugate. The modified antibody-drug conjugate according to the invention can accurately deliver the drug to a target cell due its high specificity to antigen, and thus can increase the therapeutic effect of the drug. Also, it can increase the usability of drugs, particularly anticancer drugs, the use of which is restricted due to their toxicity, despite their high efficacy. Moreover, the invention relates to a composition for treatment of diseases, particularly cancers, which comprise the modified antibody-drug conjugate.

Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 200 by having at least 70% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal amacrine bipolar cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.

Abstract: Described herein are constructs used for liver-specific expression of a transgene.

Abstract: This disclosure describes compositions and methods for delivering and localizing therapeutic agents to therapeutic targets. This disclosure also provides multivalent forms of cationic dyes (“cationic dye multimers”) and methods by which these compounds can be used to treat joint injuries.

Abstract: Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable of producing a fluorescent signal upon excitation with light of an appropriate wavelength. Also provided are in vivo and in vitro imaging methods using such imaging agents.

Abstract: A particle usable as T1 and T2 contrast agents is provided. The particle is a gadolinium silicide (Gd5Si4) particle that is ferromagnetic at temperatures up to 290 K and is less than 2 ?m in diameter. An MRI contrast agent that includes a plurality of gadolinium silicide (Gd5Si4) particles that are less than 1 ?m in diameter is also provided. A method for creating gadolinium silicide (Gd5Si4) particles is also provided. The method includes the steps of providing a Gd5Si4 bulk alloy; grinding the Gd5Si4 bulk alloy into a powder; and milling the Gd5Si4 bulk alloy powder for a time of approximately 20 minutes or less.

Abstract: The invention relates to an enzymatically responsive product that includes an amino acid residue conjugated to a magnetic particle, wherein the amino acid residue is phosphorylated or sulfated or comprises an ester-moiety linked via peptide bond. Compositions containing the enzymatically responsive product, and the use thereof for separating distinct types of mammalian cells (e.g., cancer cells from normal cells), for treating a cancerous condition, and imaging cancer cells are also disclosed.

Abstract: A microfluidic device for generating mi-crobubbles includes a substrate and a microfluidic channel embedded in the substrate. The microfluidic channel includes a plurality of fluid inlets, at least one bubble formation outlet having a nozzle with an adjustable diameter, and a flow focusing junction in fluid communication with the plurality of fluid inlets and the bubble formation outlet. A method for mass producing monodisperse microbubbles with a microfluidic device includes supplying a flow of dispersed phase fluid into a first fluid inlet of a microfluidic channel, supplying a flow of continuous phase fluid into a second fluid inlet of the microfluidic channel, and adjusting a diameter of a nozzle to obtain a plurality of monodisperse microbubbles having a specified diameter.

Abstract: The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

Abstract: The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.

Abstract: Disclosed herein are nanoparticles and method for manufacturing the same. The nanoparticle is essentially composed of albumin and polyethylene glycol, wherein the albumin is covalently crosslinked with the polyethylene glycol.

Abstract: Embodiments of this disclosure include systems, methods, and kits for sterilizing in vivo catheters using an optical fiber to deliver UV light. In an embodiment, a method for sterilizing a catheter with at least a first lumen, includes inserting a distal end of a fiber optic cable into a fiber insertion port of a catheter connector attached to a hub of the first lumen, flushing the first lumen with fluid from a fluid source, inserting the fiber optic cable into the first lumen until a stopper of the fiber optic cable is adjacent to the fiber insertion port, providing light to the fiber optic cable from a light source after the fiber optic cable is inserted into the first lumen, withdrawing the fiber optic cable from the first lumen while the light is provided, and ceasing to provide light to the fiber optic cable after the fiber optic cable is withdrawn from the first lumen. The disclosure is also applicable to catheters with multiple lumens and to catheters accessed through subcutaneous ports.

Abstract: A disinfectant appliance has a plurality of chlorite absorbent particles, a plurality of redox resin particles, and at least one absorbent material combined such that the absorbent material allows and can promote: infusion of water into the disinfectant appliance; release of the chlorite from the chlorite absorbent particles into the water to form a chlorite comprising solution; contacting of the chlorite comprising solution with the redox resin particles; and the expulsion of ClO2 comprising solution from the disinfectant appliance onto a surface to be disinfected. The disinfectant appliance can include a storage section and can include a handle. The disinfectant appliance can be in the form of a wipe or sponge that can be contacted with a surface suspected of being infected.

Abstract: The present invention relates to malodor reduction compositions and methods of making and using same. The malodor reduction compositions are suitable for use in a variety of applications, including use in consumer products, for example, air freshening compositions, laundry detergents, fabric enhancers, surface cleaners, beauty care products, dish care products, diapers, feminine protection articles, and plastic films for garbage bags. Such malodor control technologies do not unduely interfere with the scent of the perfumed or unperfumed situs that is treated with the malodor control technology.

Abstract: A scent dispenser may comprise a vial retaining mechanism, a heating element, vial sensor, and a controller. The vial retaining mechanism includes a vial coupling that removeably retains a vial containing a scented solution. The includes a wick extending from a cavity of the vial through an opening of a neck of the vial. The heating element is shaped to receive and heat the wick of the vial. The vial sensor includes an array of sensor pads that are arranged in alignment with the vial retained by the vial coupling. The controller is electrically coupled to the heating element and electrically coupled to the array of sensor pads. The controller regulates a temperature level of the heating element, and receives signals from the array of sensor pads and processing the signals to determine a fluid level of the vial.

Abstract: An aromatherapy nebulizing diffuser includes a bottom shell, a electric fan mounted in the bottom shell, a fluid container supported on the bottom shell, a cap caped on the fluid container, a oscillator mounted in the fluid container for oscillating a contained aromatic fluid into a fine mist of aromatic fluid droplets, and an air guide mounted in the fluid container and having a horizontally extended air outlet that mates with a curved inside wall portion of the cap to create a curved air flow path that guides the intake flow of air to strike against the inside wall of the cap and the container body and to further increase the air pressure for lifting the created fine mist of aromatic fluid droplets efficiently.

Abstract: The invention provides a method of making flexible bioresorbable foam having hemostatic properties and a preselectable in-vivo residence time. A blend of crosslinked collagen blended and a hyaluronic acid component is prepared. The blend is mixed with water to form a suspension. The blend is freezed and lyophilized at less than about 0° C. Next, the blend is crosslinked. The product is then sterilized and chain scission is performed by bombardment with gamma rays or a beam of electrons.

Abstract: The present invention relates to a process for producing a hydroxy amino polymer comprising the steps: a) Reaction of an H functional starter compound bearing at least one Zerewitinoff active H atom with an unsaturated, cyclical carboxylic acid anhydride and at least one alkylene oxide compound for obtaining a prepolymer bearing hydroxyl groups, b) Addition of a primary amine and/or of ammonia to the double bond(s) of the prepolymer bearing hydroxyl groups obtained according to step a) for obtaining the hydroxy amino polymer, wherein the ratio of added amino groups to hydroxyl groups in a hydroxy amino polymer is at least 0.6. Furthermore, the invention relates to a hydroxy amino polymer, which can be achieved according to this process as well as a polyurea/polyurethane system, which contains such a hydroxy amino polymer.

Abstract: The present invention relates to a magnesium alloy having controlled corrosion resistance properties, which comprises magnesium (Mg) and an alloying element and includes a magnesium phase and a phase composed of magnesium and the alloying element, wherein the difference in electrical potential between the magnesium phase and the phase composed of magnesium and the alloying element is greater than 0 V but not greater than 0.2 V.

Abstract: A valve in the form of a medical device, article, or implant that is composed wholly or partly of a biomaterial, the biomaterial comprising a polyurethane or polyurethane urea elastomeric composition having a plurality of soft segments and hard segments, such that the plurality of soft segments are each derived from at least one block copolymer segment of Formula 1 and optionally an additional polyol or polyamine. The valve may include a plurality of valve leaflets and a support structure with one or more of the valve leaflets being composed wholly or partly of the biomaterial.

Abstract: A biodegradable scaffold, a low-molecular weight thioketal, and a method of forming a biodegradable scaffold are provided. The biodegradable scaffold includes a thioketal and an isocyanate, where the thioketal is linked to the isocyanate to form the scaffold. The low-molecular weight thioketal includes 2,2-dimethoxypropane and thioglycolic acid, wherein the thioketal includes at least two hydroxyl terminal groups. The method of forming the biodegradable scaffold includes blending a thioketal with an excess isocyanate, forming a quasi-prepolymer, mixing the thioketal, the quasi-prepolymer, and a ceramic, and then adding a catalyst to form the biodegradable scaffold. The thioketal is a low-molecular weight thioketal having at least two hydroxyl terminal groups.

Abstract: The present invention provides materials and methods that can serve as a prosthetic and/or, for tissue engineer applications, as a supporting matrix in the stabilization of the myocardium.

Abstract: A bone void filler material is provided for sustained release of a therapeutic agent. The bone void filler material comprising a biodegradable matrix having ceramic cement beads comprising calcium sulfate, and ceramic particles disposed within the matrix. The ceramic cement beads are loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed.

Abstract: Bone repair compositions comprising bone particles and periosteum tissue. The bone particles may be demineralized, and may comprise powder or fibers from cortical bone or from cancellous bone. The periosteal tissue can be micronized periosteal tissue, and may comprise periosteal powder, particulates, pieces, or combinations thereof. The bone repair composition can further comprise bone chips, mineralized cancellous bone, or additional materials. The present technology also provides methods of repairing a bone defect, comprising administering a bone repair composition to the site of the bone defect.

Abstract: A method for preparing tissue, in particular pericardial tissue, in particular for use as a sealing means for a heart valve prosthesis for paravalvular leaks, characterised in that the tissue, in particular pericardial tissue, is decellularized (4), subjected to a cross-linking (6) with a glutaraldehyde-containing solution, and subjected to a shape- and a structure-stabilising step (7, 8, 9). The invention also relates to a heart valve prosthesis.

Abstract: Provided herein are bone grafts and methods of making and using the same, as well as products and kits that include such bone grafts. In particular, bone grafts are provided that include osteogenic stem cells in a mix of osteoinductive demineralized bone matrix and osteoconductive cortico-cancellous chips.

Abstract: The invention relates to a novel chemical composition comprising living cells combined with biocompatible fibres and biocompatible components which are optimally chemically formulated to repair damaged human or animal tissue.

Abstract: Due to the size and complexity of tissues such as the spinal cord and articular cartilage, specialized constructs incorporating cells as well as smart materials may be a promising strategy for achieving functional recovery. Aspects of the present invention describe the use of an electroactive, or piezoelectric, material that will act as a scaffold for stem cell induced tissue repair. Embodiments of the inventive material can also act alone as an electroactive scaffold for repairing tissues. The piezoelectric material of the present invention acts as a highly sensitive mechanoelectrical transducer that will generate charges in response to minute vibrational forces.

Abstract: Provided is a bioimplant which is capable to inhibit the biofilm formation over a long period of time after an operation. The bioimplant of the present invention comprises a base material of metal, ceramic, or plastic and a thermal spraying film of a calcium phosphate-based material formed at least partially thereon and the silver concentration in the thermal-spray film is 0.05 wt % to 3.00 wt %.

Abstract: A bone void filler material is provided that is configured for sustained release of a therapeutic agent. The bone void filler material comprises a biodegradable matrix having ceramic particles and cement beads disposed within the matrix, the cement beads loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed.

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Abstract: A balloon catheter, in particular a balloon catheter for angioplasty, the balloon having an inner or outer surface modified by means of a photoactivation reaction.

Abstract: A composite wire product includes a biodegradable parent material which forms the bulk of the cross-sectional area of the wire, and a central fiber or filament of a slower-degrading or non-biodegradable material runs throughout the length of the wire. This central filament promotes the mechanical integrity of an intraluminal appliance or other medical device made from the wire product throughout the biodegradation process by preventing non-absorbed parent material from dislodging from the central filament. Thus, the present wire design enables the creation of medical devices that are designed to improve in flexibility toward a more natural state over the course of healing, while also controlling for the possibility of non-uniform in vivo erosion.

Abstract: A surgical suction device includes a vacuum source, hose member, vacuum adaptor, and suction attachment. The suction attachment includes each of a bottom layer, middle layer, and a top layer. The bottom layer and the top layer are made of an absorptive material. The middle layer includes a system of microtubules that are in fluid communication with the vacuum source via several apertures located on its top surface. When the device is in use, the bottom layer is in contact with the soft tissue that is being operated on. When the vacuum source is turned on, suction is provided through the vacuum apertures on top of the middle layer via the microtubules. The suction persists through the top layer, and any fluid in the surgical site above the top layer is sucked through the top layer into the vacuum apertures, through the microtubules, and out of the suction attachment.

Abstract: A system includes a chest tube drainage system comprising a first chamber in fluid communication with a port connectable to a chest tube, a second chamber in fluid communication with a port connectable to a suction device, and a fluid seal connected to and disposed between the first chamber and the second chamber. The system also includes one or more gas sensors attached to the chest tube drainage system, the one or more gas sensors configured to detect at least one of gaseous carbon dioxide and gaseous oxygen, a controller connected to the one or more gas sensors, and at least one indicator coupled to the controller. The controller is configured to determine if a threshold level of carbon dioxide is exceeded, and to activate the at least one indicator if the threshold level of carbon dioxide is not exceeded.

Abstract: A lavage handle for facilitating at least one of an irrigation function and a suctioning function at a target zone preferably includes a portable body, a power-operated fluid-displacing mechanism in communication with said body wherein said fluid-displacing mechanism has one of a first operating mode for inducing outward irrigation of fluid towards the target zone and a second operating mode for inducing inward suction of fluid from the target zone. An actuation mechanism is located at said body and operable communicated with said fluid-displacing mechanism such that said fluid-displacing mechanism is selectively operated in at least one of said first operating mode and said second operating mode. The actuation mechanism may include an irrigation-inducing mechanism and/or a suction-inducing mechanism.

Abstract: A combination therapy pad that includes a first layer and a second layer operatively coupled to the first layer. A fiber-optic array is disposed between the first layer and the second layer. A third layer is operatively coupled to the first layer. The third layer includes a vacuum tube in fluid communication with a vacuum source and a therapeutic fluid tube in fluid communication with a therapeutic fluid source. The third layer provides at least one of vacuum therapy and therapeutic fluid treatment to a wound area.

Abstract: A blood processing filter for removing undesirable components from liquid containing a blood component or blood, comprises a sheet-shaped filter element, and a container that includes an inlet-side container element and an outlet-side container element that are disposed to clamp the filter element, and has an internal space separated by the filter element into an inlet space and an outlet space. The filter element includes a pair of filtering surfaces disposed on the inlet space side and the outlet space side, and an end surface along a periphery of the pair of the filtering surfaces, and the inlet-side container element and the outlet-side container element are provided with a gripper that clamps and compresses outer edge portions of the pair of filtering surfaces, and adheres to the end surface with melt resin, and a part of the container is provided with a steam-permeable portion having steam permeability.

Abstract: A hands-free breast pump system is disclosed. A breast shield having an adhesive inner surface for adhering to a woman's breast is disclosed. The breast shield may be connected to an adapter for transferring a vacuum generated by a pump to the breast. The adapter also allows milk expressed from the breast to drain from the adapter to a container. In the alternative, the breast shield may form part of a breast shield adapter system which is connected to a conventional breast shield by a drain line so that a conventional breast pump system is used to supply a vacuum and to collect the milk.

Abstract: A system and method of drawing blood from the heart of a patient. The system includes a blood pump, an outflow cannula, and a flexible cannula assembly. The flexible cannula assembly includes a cannula body, a tip, and first and second anchors. The cannula body includes a proximal end coupled to the inlet of the blood pump, a distal end including a first locking element coupled to the tip. The first anchor has a first plurality of arms and is coupled to the tip and adapted to engage the internal surface of the heart wall. The second anchor includes a second plurality of arms and a second locking element and is slidably positioned on the outer wall of the cannula body and adapted to engage the first locking element of the distal end of the cannula body to couple the second anchor to the external surface of the heart wall.

Abstract: Devices, systems and methods for establishing a blood flow conduit between a chamber in a heart of a patient and a remote location. A blood inflow cannula having an outer surface and proximal and distal end portions. The distal end portion is configured for insertion into the chamber of the heart. First and second anchor elements have respective maximum width dimensions extending outwardly from the outer surface of the cannula. The first anchor element is positioned more distally than the second anchor element defining a tissue receiving space therebetween. The maximum width dimension of the first anchor element may be larger than the maximum width dimension of the second anchor element in use. The first anchor element is configured to be positioned inside the heart chamber and the second anchor element is configured to be positioned outside the heart chamber with heart tissue held in the tissue receiving space therebetween.

Abstract: The disclosure relates to a pump for implantation into a vessel or a heart, with the pump being introduced in a first state into the vessel or heart in order then be functionally changed over to a second state in the vessel or in the heart, having a drive part and a delivery part, where the drive part is not functional in the first state and becomes functional as a result of the changeover to the second state, wherein the drive part has an electric motor, where the electric motor is embodied as a wet rotor, and where, in the first state, the rotor of the electric motor and the stator of the electric motor are arranged so as to be separate from one another, and where the rotor of the electric motor is moved into the stator of the electric motor in the second state, where the rotor can drive the delivery part in the second state.

Abstract: Techniques for mounting a sensor are disclosed. In some implementations, a molded interconnect device carries a sensor for transducing a position of a rotor of the implantable blood pump. The molded interconnect device includes one or more integrated electronic circuit traces configured to electrically connect the Hall sensor with a printed circuit board of the implantable blood pump, and the molded interconnect device is configured to be mounted to the printed circuit board.

Abstract: Disclosed are systems for wireless energy transfer including transcutaneous energy transfer. Embodiments are disclosed for electrical connections between an implanted wireless receiver and an implanted medical device powered by the receiver. Methods for manufacturing and using the devices and system are also disclosed.

Abstract: The present disclosure describes for at least two zones of selective thermal therapy of the body. Three-port extracorporeal circuits are described that can be used to establish at least two zones of selective thermal therapy of the body. The example three-port extracorporeal circuit includes a branching section that provides for setting the temperature of blood injected into two different portions of the body at differing temperature levels, to provide at least two zones of selective thermal therapy.

Abstract: Methods and systems are provided automatically removing air from a collection container for a blood product. The system comprises a disposable flow circuit including a tubing in fluid communication with the collection container and a durable hardware component. A programmable controller operates the pump in a first/forward direction to flow the target product into the collection container; determines that substantially all the target product has been pumped into the collection container; and operates the pump in the first/forward direction to pump a chase volume of air into the collection container along with any target product remaining in the tubing. In one embodiment, after the chase volume of air is pumped into the collection container, the controller operates the pump in a second/reverse direction for removing air from the collection container, and stops operation of the pump when the amount of air removed from the collection container is substantially equal to the residual volume of air.

Abstract: The present disclosure describes flow stagnation control components that allow improved flow control in systems including injection members, while also limiting the creation of regions of little to no flow in the vasculature, resulting in low flow zones or dead zones. The flow stagnation control components can be formed as an imposed minimum conductance component or a controlled flow partitioning system.

Abstract: The present invention provides a filter for separating particles and/or catalyzer for particle reaction in a fluid. The device comprising array of passageways fabricated on a die wherein the passageway size is controlled by actuators. The passageway size is monitored and the actuators controlling the passageway size are activated conditionally upon the passageway size monitoring. Using movable actuators the passageway can achieve passageway size that is less then the fabrication minimal resolution. Proper locating, setting and/or activation of the actuators create passageways that can perform filtration of particles, trapping of particles and catalyzing particles reaction.